Self-Expanding Peripheral Stent System Improves Implantation for Endovascular Treatments

By HospiMedica International staff writers
Posted on 28 Jul 2022

Image: Pulsar-18 T3 self-expanding peripheral stent system has received FDA approval (Photo courtesy of BIOTRONIK)

An innovative peripheral self-expanding stent system is designed to improve implantation procedures for endovascular treatments.

BIOTRONIK Inc.’s (Lake Oswego, OR, USA) Pulsar-18 T3 stent system uniquely combines three technologies. A 4-French low-profile delivery system may decrease the risk of access site complications and reduce the need for closure devices when compared to 6-French devices. The tri-axial system with braided shaft design facilitates stable and accurate implantation of the clinically proven Pulsar stent. With its thin struts and low chronic outward force (COF), the Pulsar-18 stent contributes to a reduced mean area of restenosis.

The redesigned Pulsar-18 T3 stent system offers physicians an intuitive and ergonomic wheel-operated handle for one-handed stent release enhancing the ability to control deployment. While the stent system has been redesigned with new features to enhance deployment, it builds on the established Pulsar stent performance. Data highlights the long-term safety and efficiency of the Pulsar stent, showing freedom from target lesion revascularization rate of 89.3% and no major target limb amputations at 24 months.

The Pulsar-18 T3 stent system is indicated for use to improve luminal diameter in patients with symptomatic de novo, restenotic or occlusive lesions located in the superficial femoral or proximal popliteal arteries, with reference vessel diameters from 3.0 to 6.0 mm and total lesion lengths up to 190 mm. BIOTRONIK will offer the Pulsar-18 T3 in up to a 200 mm stent length for treatment of long lesions.

"The Pulsar-18 T3 stent system is an innovative solution that delivers clinically proven performance – providing effective therapy that is easy to use for physicians while minimizing metal burden and may reduce the risk of restenosis for patients," stated David Hayes, M.D., Chief Medical Officer, BIOTRONIK, Inc.

"I was immediately impressed by the new concept of the Pulsar-18 T3 system," said Dr. Koen Deloose, Head of the Department of Vascular Surgery AZSint Blasius Hospital Dendermonde. "The combination of having a very ergonomic handle combined with a tri-axial system and also everything in a 4-French concept was, for me, quite unique."

Related Links:
BIOTRONIK Inc.